View DividendMYND Life Sciences マネジメントマネジメント 基準チェック /24現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間4.2yrs取締役会の平均在任期間4.8yrs経営陣の近況お知らせ • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.お知らせ • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.お知らせ • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.お知らせ • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.お知らせ • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.お知らせ • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.すべての更新を表示Recent updatesお知らせ • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.お知らせ • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.お知らせ • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.お知らせ • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.お知らせ • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.お知らせ • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.お知らせ • Oct 27MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc.MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc. on October 25, 2023. The proposed merger will be preceded by independent third-party valuations of both companies. Arrangements within each company will be negotiated by subcommittees of unconflicted Directors from both CAVA and MYND and it will require affirmative votes by the Boards of Directors of both companies. It is anticipated the transaction will be completed in Q1 2024.お知らせ • Jan 10MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023.CEOMYND Life Sciences CEOがいない、あるいは彼らに関するデータがない。リーダーシップ・チーム名称ポジション在職期間報酬所有権Wilfred JefferiesCo-Founder & Chief Science Officer5.3yrsCA$240.00kデータなしLih-Ming TamCFO & Senior Controller4.1yrsCA$82.08kデータなしChaahat SinghSenior Operations & Research Manager4.2yrsデータなしデータなしIryna SaranchovaChief Clinical Officerno dataデータなしデータなしもっと見る4.2yrs平均在職期間経験豊富な経営陣: MYND.Fの経営陣は 経験豊富 であると考えられます ( 4.2年の平均在職年数)。取締役名称ポジション在職期間報酬所有権Mark GeyerMember of Scientific Advisory Board4.8yrsデータなしデータなしMichael BrownsteinMember of Scientific Advisory Board4.8yrsデータなしデータなしJohn CampbellDirector5.3yrsデータなしデータなしRoslyn Ritchie-DerrienIndependent Director5.3yrsデータなしデータなしJohn TrowsdaleMember of Scientific Advisory Board4.8yrsデータなしデータなしScott NicollIndependent Director4.4yrsデータなしデータなしLaurie BakkeIndependent Non Executive Director2.2yrsデータなしデータなしLana HoogenboomDirector1.3yrsデータなしデータなしもっと見る4.8yrs平均在職期間経験豊富なボード: MYND.Fの 取締役会 は 経験豊富 であると考えられます ( 4.8年の平均在任期間)。View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/11 23:41終値2025/12/12 00:00収益2024/07/31年間収益2023/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MYND Life Sciences Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.
お知らせ • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.
お知らせ • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.
お知らせ • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.
お知らせ • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
お知らせ • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
お知らせ • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.
お知らせ • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.
お知らせ • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.
お知らせ • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.
お知らせ • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
お知らせ • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
お知らせ • Oct 27MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc.MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc. on October 25, 2023. The proposed merger will be preceded by independent third-party valuations of both companies. Arrangements within each company will be negotiated by subcommittees of unconflicted Directors from both CAVA and MYND and it will require affirmative votes by the Boards of Directors of both companies. It is anticipated the transaction will be completed in Q1 2024.
お知らせ • Jan 10MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023.